Key PointsModerna’s personalized melanoma vaccine, paired with Merck’s Keytruda, cut the risk of recurrence or death by 42% in a Phase 3 trial.
Chung toi hien cong khai y chinh. Tao tai khoan mien phi de doc toan bo bai viet, luu, thao luan va ket noi voi boi canh thi truong va OSINT.
